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Biomarkers for Sepsis
S. LaRosa
Rhode Island Hospital, Providence, USA
Manifestations of the Systemic Inﬂammatory Response
Syndrome (SIRS) (leukocytosis, hyperthermia, tachycardia
and tachypnea) can be present in both non-infectious and
infectious conditions and do not predict those subjects at
high risk for death. Readily available biomarkers can help
the practicing ID physician predict the likelihood of infection
and a poor outcome. Unexplained hypophosphatemia and
eosinopenia are common ﬁndings in the setting of bacterial
infection. Coagulation abnormalities including elevated D-
dimer, unexplained thrombocytopenia, Protein C deﬁciency
and prolonged prothrombin time (PT) are present to a
greater extent in patients with a deﬁnite focus of infection
or bacteremia than in those without. Protein C deﬁciency
occurs early in the setting of infection and the severity
predicts outcome. Lactic acidemia is present in the set-
ting of sepsis and the inability to clear it after appropriate
antibiotics and aggressive ﬂuid resuscitation predicts a poor
outcome.
Newer approved biomarkers for sepsis include serum pro-
calcitonin (PCT) and the Endotoxin Activity Assay (EAA).
Serum PCT has been shown to have better sensitivity and
speciﬁcity than the more commonly ordered C-reactive pro-
tein (CRP) in distinguishing SIRS from sepsis. PCT levels have
also been used to shorten the duration of antibiotic therapy.
The EAA assay is elevated in 85% of patients with severe sep-
sis and levels >0.6 are associated with the highest mortality.
A number of additional biomarkers for sepsis are actively
being investigated. In a clinical trial of a biomarker panel,
a score composed of neutrophil-gelatinase —associated
lipocalin (NGAL) in concert with IL-1 receptor antagonist
(IL-1ra) and Protein C had the highest diagnostic accu-
racy for severe sepsis. Levels of the biomarkers gelsolin,
angiopoietin 2 and inter-alpha inhibitors are associated with
sepsis severity and could potentially serve as theragnostics.
Sepsis-induced immunosuppression and propensity towards
secondary infection may be predicted by decreased mono-
cytic HLA-DR expression and reversed with treatment with
GM-CSF.
doi:10.1016/j.ijid.2010.02.2192
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Biomarkers for the Diagnosis of TB
J. Friedland
Imperial College London, London, United Kingdom
Many patients with tuberculosis are treated empirically
and failure to diagnose infection is a cause of morbidity and
mortality. Tuberculosis is a great mimic of other infectious
and non-infectious medical conditions. It may be difﬁcult
to distinguish active disease from latent infection from pre-
vious and even treated tuberculosis. There is also a major
problem in knowing if prophylactic therapy and new vac-
cination programmes are effective since the time course
of the development of active infection is measured over
o
h
b
its e317
ecades. For all these reasons, there is great interest in the
evelopment of novel biomarkers in tuberculosis. To date,
he main biomarkers used in infection are skin tests which
ely on delayed hypersensitivity reactions and interferon
ssays. All these tests have limitations in terms of sensi-
ivity and ability to distinguish different forms of infection.
nitial interest in biomarkers focused on single markers such
s adenosine deaminase. It has become apparent that such
arkers do not provide sufﬁcient speciﬁcity. After brieﬂy
eviewing the topic, I shall focus on the current interest in
eﬁning multiple biomarkers for the diagnosis of tuberculo-
is. There has been interest in transciptomics, metabolomics
nd proteomics to deﬁne disease. Proteomics is particu-
arly attractive as there is the potential to develop tools
uch as dipsticks which are suitable for use in resource-
oor areas from such studies. Some data will be presented
rom our unpublished studies using proteomics to distin-
uish active and latent infection. An alternative, interesting
pproach that will be considered is the development of spe-
iﬁc immune proﬁles that reﬂect either latent or active
nfection with tuberculosis. The potential and current appli-
ation of biomarkers for tuberculosis is an exciting area and
eems likely to provide a future step-change in the diagnosis
f this global infection
oi:10.1016/j.ijid.2010.02.2193
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linical Utility of Biomarkers in Fungal Infection
. Patterson
University of Texas Health Science Center at San Antonio,
an Antonio, TX, USA
Biomarkers are important means for the diagnosis of
nvasive mycoses as cultures may not be positive even in
he setting of signiﬁcant infection. Furthermore, invasive
rocedures which may be necessary to establish deﬁnitive
vidence of infection are often reluctantly undertaken in
everely immunosuppressed patients. For some mycoses,
uch as Cryptococcus and Histoplasma, the detection of
irculating polysaccharide antigen has proven a very use-
ul target for both diagnosis and response to therapy. More
ecently biomarkers have been used to diagnose opportunis-
ic pathogens such as Candida and Aspergillus. A major focus
as been on measurement of Aspergillus galactomannan
rom serum and other body ﬂuids to establish a diagnosis of
nvasive aspergillosis. Serial measurements of galactoman-
an have been shown to correlate with progressive infection
r with successful outcomes of therapy in both pre-clinical
odels as well as in human infections. A number of fac-
ors signiﬁcantly reduce levels of circulating galactomannan
ncluding the use of mould-active antifungal therapy or pro-
hylaxis, immune status of the host and importantly extent
f infection. The test may not be positive despite invasive
nfection, particularly if localized to the lung or if anti-
ould agents are administered. PCR based-methods have
een developed for Aspergillus and Candida but the lack
f standardization and limited external validation have also
ampered utility of that approach. A non-speciﬁc fungal
iomarker, 1,3-beta, D-glucan, that it detected using a mod-
ﬁcation of the limulus lysate assay, is present in many
